Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Oki

Showing results (41-50 of 164) with videos related to

Pageof 17
Sort By:
Cancer Research|May 19, 2006
Silencing of bidirectional promoters by DNA methylation in tumorigenesisJingmin Shu, Jaroslav Jelinek, Hao Chang, et al.
European Journal of Haematology|September 10, 2009
R-CHOP therapy for MALT lymphoma of the rectumDai Chihara, Yoshitoyo Kagami, Yasuhiro Oki, et al.
British Journal of Haematology|August 10, 2016
Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS InvolvementDai Chihara, Nathan H Fowler, Yasuhiro Oki, et al.
Cancer Treatment and Research Communications|November 14, 2020
Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib studyMichael Schaffer, Shalini Chaturvedi, Cuc Davis, et al.
Hematological Oncology|September 14, 2018
Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotinDai Chihara, Shannon Wong, Tatyana Feldman, et al.
Human Pathology|January 21, 2014
Indolent peripheral T-cell lymphoma involving the gastrointestinal tractVasiliki Leventaki, John T Manning, Rajayalakshmi Luthra, et al.
Leukemia & Lymphoma|October 29, 2009
Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathyDai Chihara, Yasuhiro Oki, Shouji Ine, et al.
Cancer Science|November 10, 2007
Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphomaYasuhiro Oki, Michinori Ogura, Harumi Kato, et al.
Haematologica|March 31, 2015
Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphomaYasuhiro Oki, Anas Younes, Javier Knickerbocker, et al.
Cancer|December 19, 2007
Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphomaYasuhiro Oki, Barbara Pro, Luis E Fayad, et al.
Pageof 17

Showing results (41-50 of 164) with videos related to

Sort By:
Pageof 17
Cancer Research|May 19, 2006
Silencing of bidirectional promoters by DNA methylation in tumorigenesisJingmin Shu, Jaroslav Jelinek, Hao Chang, et al.
European Journal of Haematology|September 10, 2009
R-CHOP therapy for MALT lymphoma of the rectumDai Chihara, Yoshitoyo Kagami, Yasuhiro Oki, et al.
British Journal of Haematology|August 10, 2016
Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS InvolvementDai Chihara, Nathan H Fowler, Yasuhiro Oki, et al.
Cancer Treatment and Research Communications|November 14, 2020
Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib studyMichael Schaffer, Shalini Chaturvedi, Cuc Davis, et al.
Hematological Oncology|September 14, 2018
Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotinDai Chihara, Shannon Wong, Tatyana Feldman, et al.
Human Pathology|January 21, 2014
Indolent peripheral T-cell lymphoma involving the gastrointestinal tractVasiliki Leventaki, John T Manning, Rajayalakshmi Luthra, et al.
Leukemia & Lymphoma|October 29, 2009
Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathyDai Chihara, Yasuhiro Oki, Shouji Ine, et al.
Cancer Science|November 10, 2007
Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphomaYasuhiro Oki, Michinori Ogura, Harumi Kato, et al.
Haematologica|March 31, 2015
Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphomaYasuhiro Oki, Anas Younes, Javier Knickerbocker, et al.
Cancer|December 19, 2007
Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphomaYasuhiro Oki, Barbara Pro, Luis E Fayad, et al.
Pageof 17